2. Signaling Pathways
  3. GPCR/G Protein
    MAPK/ERK Pathway
  4. Ras

Ras

Ras

Related Products

PDF 2.6 MB

Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

Ras Isoform Specific Products:

Ras Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-175870
    pan-KRAS-IN-18
    		Inhibitor
    pan-KRAS-IN-18 (Compound 14-1) is a pan-KRAS inhibitor. pan-KRAS-IN-18 has potent antitumor activities and significantly inhibits the proliferation of wild-type and mutant (such as KRASG12D, KRASG12V and KRASG12C) cancer cells. pan-KRAS-IN-18 effectively inhibits tumor growth in GP2D and Panc0403 xenograft mouse models.
    pan-KRAS-IN-18
  • HY-164802
    Pan-RAS-IN-7
    		Inhibitor
    Pan-RAS-IN-7 (Compound D101) is a pan RAS inhibitor that can be used for the synthesis of ADCs. Pan-RAS-IN-7 can be utilized in cancer research.
    Pan-RAS-IN-7
  • HY-176419
    KRAS inhibitor-42
    		Inhibitor
    KRAS inhibitor-42 (compound 8) is a potent USP7 inhibitor. KRAS inhibitor-42 has high affinity against GDP-bound KRASG12D with a Ki of 2.7 μM.
    KRAS inhibitor-42
  • HY-112493
    KRas G12C inhibitor 3
    		Inhibitor
    KRas G12C inhibitor 3 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.
    KRas G12C inhibitor 3
  • HY-172221
    SOS1-IN-18
    		Inhibitor
    SOS1-IN-18 (Compound 8) is the inhibitor for Son of Sevenless 1 protein (SOS1) with a KD of 2.6 nM, and inhibits SOS1-KRAS G12C interaction with an IC50 of 3.4 nM. SOS1-IN-18 inhibits the phosphorylation of ERK in H358 with an IC50 of 31 nM, inhibits the proliferation of H358 with an IC50 of 5 nM.
    SOS1-IN-18
  • HY-168678
    PROTAC K-Ras Degrader-6
    		Inhibitor
    pan-KRAS degrader 5 (compound 102) is a potent cereblon-based KRAS PROTAC degrader, with a DC50 of <100 nM. pan-KRAS degrader 5 shows anticancer effects. (Pink: ligand for target protein (HY-168679); Black: linker (HY-168670); Blue: E3 ligase ligand (HY-W580113)).
    PROTAC K-Ras Degrader-6
  • HY-149847
    JH530
    JH530 is an effective methuosis inducer that inhibits the triple-negative breast cancer (TNBC) cells proliferation by causing intracellular complete vacuolization. JH530 has anti-tumor activity and can be used for cancer research.
    JH530
  • HY-145048
    SOS1-IN-5
    		Inhibitor
    SOS1-IN-5 is a potent inhibitor of SOS1. SOS1-IN-5 is a pyrimidobicyclic derivative. SOS1-IN-5 blocks the activation of KRAS by interfering with RAS-SOS1 interaction, and achieves the purpose of broad-spectrum inhibition of KRAS activity. SOS1-IN-5 has the potential for the research of cancer diseases (extracted from patent WO2021203768A1, compound 4).
    SOS1-IN-5
  • HY-133875
    CE3F4 analog 1
    		Inhibitor 99.67%
    CE3F4 analog 1 is an analogue of CE3F4.
    CE3F4 analog 1
  • HY-171777
    Erufosine
    		Inhibitor
    Erufosine is an inhibitor of PI3K/Akt and Ras/Raf/MAPK signaling pathways. Erufosine inhibits the activity of breast cancer cell lines MCF-7 and MDA-MB 231 (IC50: 40.95/40.8 μM). Erufosine reduces the phosphorylation of PI3K (p85), Akt (PKB), and cRaf. Erufosine can be used in the study of breast cancer and myeloid leukemia.
    Erufosine
  • HY-162443
    pan-KRAS-IN-10
    		Inhibitor
    pan-KRAS-IN-10 (Compound 58) is an inhibitor for in human tumor mutated genes KRAS, which inhibits proliferation of KRAS mutated cells AsPC-1 (G12D mutant) and SW480 (G12V mutant) with IC50 of 0.7 and 0.24 nM, respectively.
    pan-KRAS-IN-10
  • HY-156528
    pan-KRAS-IN-4
    		Inhibitor
    pan-KRAS-IN-4 (compound 5) is a potent inhibitor of KRAS with IC50s of 0.37 nM (Kras G12C), 0.19 nM (Kras G12V), respectively.
    pan-KRAS-IN-4
  • HY-142511
    KRAS G12C inhibitor 34
    		Inhibitor
    KRAS G12C inhibitor 34 is a KRAS G12C inhibitor extracted from patent WO2021239058A1, compound Z1. KRAS G12C inhibitor 34 can be used for the research of cancer.
    KRAS G12C inhibitor 34
  • HY-159611
    KRAS G12C inhibitor 68
    		Inhibitor
    KRAS G12C inhibitor 68 (compound I-063) is a KRAS G12C inhibitor with an IC50 of 7 nM. KRAS G12C inhibitor 68 has anti-tumor activity.
    KRAS G12C inhibitor 68
  • HY-W041315
    CFL-120
    		Inhibitor ≥98.0%
    CFL-120 is a potent KRasG12C inhibitor. CFL-120 shows an antiproliferative effect. CFL-120 shows anticancer activity. CFL-120 has the potential for the research of lung cancer.
    CFL-120
  • HY-115907
    K20
    		Inhibitor
    K20 is a potent and selective KRas G12C inhibitor with an IC50 of 1.16 µM. K20 shows anticancer activity in H358 cells (IC50= 0.78 µM). K20 decreases the levels of phosphorylated Erk and leads to cancer cell apoptosis. K20 suppresses NCI-H358 tumor growth with a TGI of 41% without causing obvious toxicity.
    K20
  • HY-139911
    KRAS G12D inhibitor 7
    		Inhibitor
    KRAS G12D inhibitor 7 is a potent inhibitor of KRAS G12D (extracted from patent WO2021108683, compound 114) .
    KRAS G12D inhibitor 7
  • HY-178194
    SHY-855
    		Inhibitor
    SHY-855 is a pan RAS inhibitor. SHY-855 effectively prevents the binding of K-Ras proteins and other members of the Ras superfamily of small GTPases with IC50 values of 0.3-5 μM. SHY-855 effectively inhibits the phosphorylation of MEK, ERK1/2, and AKT downstream of K-Ras. SHY-855 inhibits the formation of the Ras-GTP activity complex. SHY-855 can be used to the studies of pancreatic cancer and non-small cell lung cancer.
    SHY-855
  • HY-143598
    KRAS G12C inhibitor 42
    		Inhibitor
    KRAS G12C inhibitor 42 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 42 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2020146613A1, compound 10).
    KRAS G12C inhibitor 42
  • HY-156549
    KRAS G12C inhibitor 61
    		Inhibitor
    KRAS G12C inhibitor 61 (Example 3) inhibits phospho-ERK 1/2 in MIA PaCa-2 cells with an IC50 value of 9 nM. KRAS G12C inhibitor 61 can be used for research of pancreatic, colorectal, and lung cancers.
    KRAS G12C inhibitor 61
Cat. No. Product Name / Synonyms Application Reactivity
Ras Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.